Analyst Activity – Peel Hunt Lowers Its Price Target On Circassia Pharmaceuticals PLC (LON:CIR) to GBX 150

ME Staff
-
0

Analyst Ratings For Circassia Pharmaceuticals PLC (LON:CIR)

Today, Peel Hunt lowered its price target on Circassia Pharmaceuticals PLC (LON:CIR) to GBX 150 per share.

There are 4 hold ratings, 2 buy ratings on the stock.

The current consensus rating on Circassia Pharmaceuticals PLC (LON:CIR) is Hold (Score: 2.33) with a consensus target price of GBX 175.83 per share, a potential .

Some recent analyst ratings include

  • 1/17/2017-J P Morgan Chase & Co Reiterated Rating of Neutral.
  • 9/27/2016-Numis Securities Ltd Reiterated Rating of Buy.
  • 6/21/2016-Barclays PLC initiated coverage with a Overweight rating.
  • 6/21/2016-Stifel Nicolaus was Downgraded by analysts at Stifel Nicolaus from a “Hold” rating to a “” rating.
  • 6/21/2016-Royal Bank Of Canada was Downgraded by analysts at Royal Bank Of Canada from a “Sector Performer” rating to a “” rating. They now have a GBX 105 price target on the stock, up previously from GBX 430 .
  • 5/18/2015-Canaccord Genuity Reiterated Rating of Buy.


    About Circassia Pharmaceuticals PLC (LON:CIR)
    Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. Its next-generation immunotherapy is in Phase III testing for cat allergy. Its lead asthma treatment targets substitution of GlaxoSmithKline’s (GSK’s) Flixotide pMDI. It is developing therapies targeting direct substitution of Seretide pMDI and Serevent pMDI. The Company is also developing a range treatment, including a fixed dose triple combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

    Recent Trading Activity for Circassia Pharmaceuticals PLC (LON:CIR)
    Shares of Circassia Pharmaceuticals PLC closed the previous trading session at 84.50 down -1.25 -1.46% with 12,114 shares trading hands.